DCM
MCID: DLT002
MIFTS: 81

Dilated Cardiomyopathy (DCM)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Ear diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Dilated Cardiomyopathy

MalaCards integrated aliases for Dilated Cardiomyopathy:

Name: Dilated Cardiomyopathy 12 75 24 53 59 37 29 55 6 15 38 17 33
Familial Dilated Cardiomyopathy 12 75 53 25 59 29 6 72
Idiopathic Dilation Cardiomyopathy 12 75 72
Primary Dilated Cardiomyopathy 12 29 6
Cardiomyopathy, Dilated 44 40 72
Idiopathic Dilated Cardiomyopathy 53 17
Congestive Cardiomyopathy 12 25
Dcm 53 48
Hypokinetic Dilated Cardiomyopathy, Familial 53
Primary Familial Dilated Cardiomyopathy 25
Cardiomyopathy, Familial Idiopathic 72
Familial Idiopathic Cardiomyopathy 25
Cardiomyopathy, Familial Dilated 53
Dilated Cardiomyopathy, Familial 53
Fdc 25

Characteristics:

Orphanet epidemiological data:

59
dilated cardiomyopathy
Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:12930
KEGG 37 H00294
MeSH 44 D002311
NCIt 50 C84673
SNOMED-CT 68 74368002
ICD10 33 I42.0
MESH via Orphanet 45 C536231 D002311
ICD10 via Orphanet 34 I42.0
UMLS via Orphanet 73 C0007193 C0340427
UMLS 72 C0007193 C0340427 C1449563 more

Summaries for Dilated Cardiomyopathy

KEGG : 37
Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM ("familial" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of "familial" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an "idiopathic" DCM. Current hypotheses regarding causes of "idiopathic" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with "idiopathic" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.

MalaCards based summary : Dilated Cardiomyopathy, also known as familial dilated cardiomyopathy, is related to familial isolated dilated cardiomyopathy and cardiomyopathy, dilated, 1e. An important gene associated with Dilated Cardiomyopathy is LMNA (Lamin A/C), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Aldosterone synthesis and secretion. The drugs Verapamil and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are failure to thrive and dyspnea

Disease Ontology : 12 An intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently.

Genetics Home Reference : 25 Familial dilated cardiomyopathy is a genetic form of heart disease. It occurs when heart (cardiac) muscle becomes thin and weakened in at least one chamber of the heart, causing the open area of the chamber to become enlarged (dilated). As a result, the heart is unable to pump blood as efficiently as usual. To compensate, the heart attempts to increase the amount of blood being pumped through the heart, leading to further thinning and weakening of the cardiac muscle. Over time, this condition results in heart failure. It usually takes many years for symptoms of familial dilated cardiomyopathy to cause health problems. They typically begin in mid-adulthood, but can occur at any time from infancy to late adulthood. Signs and symptoms of familial dilated cardiomyopathy can include an irregular heartbeat (arrhythmia), shortness of breath (dyspnea), extreme tiredness (fatigue), fainting episodes (syncope), and swelling of the legs and feet. In some cases, the first sign of the disorder is sudden cardiac death. The severity of the condition varies among affected individuals, even in members of the same family.

NIH Rare Diseases : 53 Dilated cardiomyopathy (DCM) is a disease of the heart muscle which primarily affects the heart's main pumping chamber, the left ventricle. It is the most common type of cardiomyopathy and typically affects those aged 20 to 60. The left ventricle of affected individuals becomes enlarged (dilated) and cannot pump blood to the body with as much force as a healthy heart can. The heart muscle also has difficulty contracting normally, which can lead to irregular heartbeats (arrhythmia), blood clots, or sudden death. Over time, the heart becomes weaker and heart failure can occur. While the cause of dilated cardiomyopathy is often unknown (idiopathic), some cases are acquired and roughly half are inherited or familial. Also, DCM can be a feature of many genetic syndromes. Familial dilated cardiomyopathy is most often inherited in an autosomal dominant pattern. Familial dilated cardiomyopathy is caused by mutations in several different genes, most commonly in the TTN gene (found in about 20% of cases). DCM treatment may include medication, pacemakers, implantable cardiac defibrillators, or heart transplantation.

Wikipedia : 75 Dilated cardiomyopathy (DCM) is a condition in which the heart becomes enlarged and cannot pump blood... more...

GeneReviews: NBK1309

Related Diseases for Dilated Cardiomyopathy

Diseases in the Rare Cardiomyopathy family:

Cardiomyopathy, Dilated, 1a Cardiomyopathy, Dilated, 3b
Cardiomyopathy, Dilated, 1b Cardiomyopathy, Dilated, 1e
Cardiomyopathy, Dilated, 1d Cardiomyopathy, Dilated, 1g
Cardiomyopathy, Dilated, 1h Cardiomyopathy, Dilated, 1i
Cardiomyopathy, Dilated, 1j Cardiomyopathy, Dilated, 1k
Cardiomyopathy, Dilated, 1l Cardiomyopathy, Dilated, 1m
Cardiomyopathy, Dilated, 1o Cardiomyopathy, Dilated, 1p
Cardiomyopathy, Dilated, 1q Cardiomyopathy, Dilated, 1w
Cardiomyopathy, Dilated, 1x Cardiomyopathy, Dilated, 1z
Cardiomyopathy, Dilated, 2a Cardiomyopathy, Dilated, 1bb
Cardiomyopathy, Dilated, 1cc Cardiomyopathy, Dilated, 1dd
Cardiomyopathy, Dilated, 1ee Cardiomyopathy, Dilated, 1ff
Cardiomyopathy, Dilated, 1r Cardiomyopathy, Dilated, 1gg
Cardiomyopathy, Dilated, 1u Cardiomyopathy, Dilated, 1v
Cardiomyopathy, Dilated, 1hh Cardiomyopathy, Dilated, 2b
Cardiomyopathy, Dilated, 1ii Cardiomyopathy, Dilated, 1jj
Cardiomyopathy, Dilated, 1kk Cardiomyopathy, Dilated, 1nn
Cardiomyopathy, Dilated, 2c Autoimmune Cardiomyopathy
Dilated Cardiomyopathy 1t Dilated Cardiomyopathy
Cardiomyopathy Due to Anthracyclines

Diseases related to Dilated Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 922)
# Related Disease Score Top Affiliating Genes
1 familial isolated dilated cardiomyopathy 36.7 TTN TPM1 TNNT2 TNNI3 SCN5A RBM20
2 cardiomyopathy, dilated, 1e 36.2 TTN TPM1 SCN5A RBM20 NKX2-5 MYH7
3 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 35.9 SCN5A MYH7 DSP DSG2
4 atrial standstill 1 35.2 TTN TNNT2 TNNI3 SCN5A PLN MYH7
5 myocarditis 34.6 TNNI3 MYH6 DSP DMD
6 campomelic dysplasia 34.1 TTN RBM20 MYH6 MYBPC3 LMNA BAG3
7 hypertrophic cardiomyopathy 34.0 TTN TPM1 TNNT2 TNNI3 SCN5A PLN
8 congenital fiber-type disproportion 34.0 MYH7 LMNA DMD
9 cardiac conduction defect 33.6 SCN5A PLN MYH7 MYBPC3 LMNA DSP
10 heart disease 33.5 TTN TNNT2 TNNI3 SCN5A NKX2-5 MYH7
11 left ventricular noncompaction 33.4 TTN TPM1 TNNT2 SCN5A NKX2-5 MYH7
12 congestive heart failure 33.3 PLN MYH7 MYH6
13 arrhythmogenic right ventricular cardiomyopathy 33.3 TTN SCN5A RBM20 PLN MYH7 LMNA
14 ventricular fibrillation, paroxysmal familial, 1 33.0 TNNT2 SCN5A NKX2-5 DSP
15 cardiac arrest 33.0 TNNT2 SCN5A PLN MYH7 MYBPC3 DSP
16 atrioventricular block 32.8 SCN5A NKX2-5 LMNA
17 restrictive cardiomyopathy 32.6 TTN TPM1 TNNT2 TNNI3 MYH7 MYBPC3
18 cardiomyopathy, familial hypertrophic, 1 32.6 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
19 sick sinus syndrome 32.4 TTN SCN5A MYH6 LMNA
20 neuromuscular disease 32.4 TTN LMNA DMD DES
21 wolff-parkinson-white syndrome 32.2 TNNI3 NKX2-5 MYH7
22 muscular disease 32.0 TTN MYH7 MYH6 LMNA DMD BAG3
23 atrial heart septal defect 32.0 NKX2-5 MYH6 DMD
24 muscular dystrophy, congenital, lmna-related 31.9 TTN LMNA DMD
25 myofibrillar myopathy 31.7 TTN LMNA DMD DES BAG3
26 familial isolated restrictive cardiomyopathy 31.6 TNNT2 TNNI3
27 first-degree atrioventricular block 31.6 SCN5A MYH7
28 rigid spine muscular dystrophy 1 31.6 TTN MYH7 DMD
29 arrhythmogenic right ventricular dysplasia, familial, 1 31.5 TTN DSP DSG2
30 aortic valve disease 1 31.5 TNNI3 NKX2-5 DSP
31 cardiomyopathy, familial hypertrophic, 4 31.5 TTN MYBPC3
32 holt-oram syndrome 31.4 NKX2-5 MYH7 MYH6
33 interatrial communication 31.4 NKX2-5 DMD
34 acute myocardial infarction 31.3 TNNT2 TNNI3 MIR499A
35 cardiac conduction disease with or without dilated cardiomyopathy 12.7
36 dilated cardiomyopathy 1t 12.7
37 cardiomyopathy, dilated, 3b 12.6
38 cardiomyopathy, dilated, 1a 12.5
39 cardiomyopathy, dilated, with woolly hair and keratoderma 12.5
40 cardiomyopathy, dilated, 1j 12.4
41 cardiomyopathy, dilated, 1x 12.4
42 cardiomyopathy, dilated, 1o 12.4
43 lmna-related dilated cardiomyopathy 12.4
44 non-familial dilated cardiomyopathy 12.4
45 syndrome associated with dilated cardiomyopathy 12.4
46 cardiomyopathy, dilated, 1l 12.4
47 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 12.4
48 cardiomyopathy, dilated, 1g 12.3
49 cardiomyopathy, dilated, 1p 12.3
50 cardiomyopathy, dilated, 1aa, with or without left ventricular noncompaction 12.3

Graphical network of the top 20 diseases related to Dilated Cardiomyopathy:



Diseases related to Dilated Cardiomyopathy

Symptoms & Phenotypes for Dilated Cardiomyopathy

Human phenotypes related to Dilated Cardiomyopathy:

59 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 failure to thrive 59 Frequent (79-30%)
2 dyspnea 59 Frequent (79-30%)
3 arrhythmia 59 Frequent (79-30%)
4 congestive heart failure 59 Frequent (79-30%)
5 cough 59 Occasional (29-5%)
6 abnormal levels of creatine kinase in blood 59 Occasional (29-5%)
7 mitral regurgitation 59 Occasional (29-5%)
8 left ventricular hypertrophy 59 Very frequent (99-80%)
9 reduced ejection fraction 59 Frequent (79-30%)
10 atrial fibrillation 59 Frequent (79-30%)
11 palpitations 59 Occasional (29-5%)
12 coronary artery atherosclerosis 59 Excluded (0%)
13 ventricular arrhythmia 59 Occasional (29-5%)
14 elevated pulmonary artery pressure 59 Occasional (29-5%)
15 left ventricular systolic dysfunction 59 Very frequent (99-80%)
16 right ventricular dilatation 59 Frequent (79-30%)
17 left bundle branch block 59 Occasional (29-5%)

MGI Mouse Phenotypes related to Dilated Cardiomyopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 BAG3 CSRP3 DES DMD DSP LMNA
2 mortality/aging MP:0010768 9.97 BAG3 CSRP3 DES DMD DSG2 DSP
3 muscle MP:0005369 9.83 BAG3 CSRP3 DES DMD DSP LMNA
4 respiratory system MP:0005388 9.17 BAG3 CSRP3 DMD LMNA MYH6 NKX2-5

Drugs & Therapeutics for Dilated Cardiomyopathy

Drugs for Dilated Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
3
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Allopurinol Approved Phase 4 315-30-0 2094
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
8
Enalaprilat Approved Phase 4 76420-72-9 6917719
9
Digoxin Approved Phase 4 20830-75-5 30322 2724385
10
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
11
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
12
Glucagon Approved Phase 4 16941-32-5
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Methyltestosterone Approved Phase 4 58-18-4 6010
15
Testosterone enanthate Approved Phase 4 315-37-7 9416
16
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
17
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
18
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
19
Adenosine Approved, Investigational Phase 4 58-61-7 60961
20
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
21
Saxagliptin Approved Phase 4 361442-04-8 11243969
22
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Uric acid Investigational Phase 4 69-93-2 1175
25 carnitine Phase 4
26 Ubiquinone Phase 4
27 Vitamins Phase 4
28 Antimetabolites Phase 4
29 Neurotransmitter Agents Phase 4
30 Angiotensin-Converting Enzyme Inhibitors Phase 4
31 Antioxidants Phase 4
32 Adrenergic alpha-Antagonists Phase 4
33 Adrenergic alpha-1 Receptor Antagonists Phase 4
34 Protective Agents Phase 4
35 calcium channel blockers Phase 4
36 Calcium, Dietary Phase 4
37 Pharmaceutical Solutions Phase 4
38 Free Radical Scavengers Phase 4
39 Lipid Regulating Agents Phase 4
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
41 Hypolipidemic Agents Phase 4
42 Anticholesteremic Agents Phase 4
43 Sodium Channel Blockers Phase 4
44 Natriuretic Peptide, Brain Phase 4
45 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
46 Cytochrome P-450 CYP3A Inhibitors Phase 4
47 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
48 Cytochrome P-450 Enzyme Inhibitors Phase 4
49 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
50 Potassium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
2 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
3 Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. Unknown status NCT01904396 Phase 4 Carnitine
4 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
5 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
6 Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
7 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
8 Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
9 A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
10 Effect of Aldosterone on Energy Starvation in Heart Failure Completed NCT00574119 Phase 4 spironolactone
11 ACC - Atrial Contribution to CRT Completed NCT00180323 Phase 4
12 Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Completed NCT01181414 Phase 4 Beta blocker/digoxine/amiodarone
13 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
14 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment
15 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
16 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
17 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
18 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
19 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Recruiting NCT03249272 Phase 4 Regadenoson;Adenosine
20 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
21 Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial Not yet recruiting NCT02948998 Phase 4 Spironolactone
22 Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance Terminated NCT01548651 Phase 4 Saxagliptin;Placebo
23 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
24 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
25 Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Unknown status NCT02654678 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
26 Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Unknown status NCT02652728 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
27 A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction Unknown status NCT01822808 Phase 3 Hydralazine;Isosorbide Dinitrate
28 Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease Unknown status NCT02652741 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
29 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
30 Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study Completed NCT02987322 Phase 2, Phase 3
31 Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy Completed NCT00333827 Phase 3 optimal therapy for cardiaca failure
32 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial Completed NCT00743639 Phase 2, Phase 3
33 Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy Completed NCT01223703 Phase 3 n-3 PUFAs;Placebo
34 Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy Completed NCT02248532 Phase 2, Phase 3
35 A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure Completed NCT00505154 Phase 3 Rosuvastatin;placebo
36 A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF) Completed NCT01311791 Phase 2, Phase 3 Standard medical therapy
37 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection Completed NCT00741156 Phase 3 Enalaprilat
38 Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study. Completed NCT01724450 Phase 3 Carvedilol;Placebo
39 Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients With Chronic Heart Failure Completed NCT00501514 Phase 3 Growth hormone
40 Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies Completed NCT01110824 Phase 3 Enalapril and carvedilol
41 Beta-Blocker Evaluation in Survival Trial (BEST) Completed NCT00000560 Phase 3 adrenergic beta antagonists
42 A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction Completed NCT02672267 Phase 3
43 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
44 Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery Completed NCT00321295 Phase 3
45 A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Recruiting NCT03439514 Phase 3 ARRY-371797
46 Impact of Continues Positive Airway Pressure Treatment in Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea (RIDA) Recruiting NCT02989181 Phase 3
47 Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF) Recruiting NCT01914081 Phase 3
48 Bisoprolol for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomized, Controlled Trial Recruiting NCT03779646 Phase 2, Phase 3 Bisoprolol Fumarate
49 PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers) Active, not recruiting NCT01857856 Phase 3 Eplerenone
50 Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy Terminated NCT01583114 Phase 3 perindopril;placebo

Search NIH Clinical Center for Dilated Cardiomyopathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Diltiazem
Inamrinone
inamrinone lactate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Dilated Cardiomyopathy cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: cardiomyopathy, dilated

Genetic Tests for Dilated Cardiomyopathy

Genetic tests related to Dilated Cardiomyopathy:

# Genetic test Affiliating Genes
1 Primary Dilated Cardiomyopathy 29 ABCC9 ACTC1 ACTN2 ANKRD1 BAG3 CSRP3 DES DSG2 EYA4 FKTN LDB3 LMNA MYBPC3 MYH6 NEXN PLN PSEN1 PSEN2 RBM20 SGCD TAZ TCAP TMPO TNNT2 TPM1 TTN VCL
2 Dilated Cardiomyopathy 29
3 Familial Dilated Cardiomyopathy 29

Anatomical Context for Dilated Cardiomyopathy

MalaCards organs/tissues related to Dilated Cardiomyopathy:

41
Heart, Bone, Testes, Bone Marrow, Endothelial, T Cells, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Dilated Cardiomyopathy:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Left Ventricle Cardiomyocytes Affected by disease, potential therapeutic candidate
2 Heart Myocardium Cardiomyocytes Affected by disease
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
4 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Dilated Cardiomyopathy

Articles related to Dilated Cardiomyopathy:

(show top 50) (show all 16031)
# Title Authors PMID Year
1
Dilated Cardiomyopathy Overview 38 71
20301486 2007
2
Cardiomyopathy, familial dilated. 38 71
16839424 2006
3
Multigenic Disease and Bilineal Inheritance in Dilated Cardiomyopathy Is Illustrated in Nonsegregating LMNA Pedigrees. 38 4
30012837 2018
4
The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. 38 4
26518443 2015
5
A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. 38 4
25852082 2015
6
Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. 38 4
25589632 2015
7
The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. 38 4
24503780 2014
8
Dilated cardiomyopathy: the complexity of a diverse genetic architecture. 38 4
23900355 2013
9
Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. 38 4
23418287 2013
10
Truncations of titin causing dilated cardiomyopathy. 38 4
22335739 2012
11
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 71
21810866 2011
12
Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. 38 4
21492761 2011
13
Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. 38 4
20864896 2010
14
Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. 38 88
20488170 2010
15
The genetics of dilated cardiomyopathy. 38 4
20186049 2010
16
Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. 38 4
20458009 2010
17
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. 38 4
20458010 2010
18
Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. 38 4
20215591 2010
19
Use of genetics in the clinical evaluation of cardiomyopathy. 38 4
19996403 2009
20
Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. 38 4
19808347 2009
21
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. 38 4
19095136 2008
22
Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. 38 4
19412328 2008
23
Dilated cardiomyopathy presenting during fetal life. 38 4
16014190 2005
24
Clinical and genetic issues in familial dilated cardiomyopathy. 38 4
15808750 2005
25
Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). 4
29904160 2018
26
Use and interpretation of genetic tests in cardiovascular genetics. 4
20937756 2010
27
The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. 9 38
20171888 2010
28
Heart failure-associated changes in RNA splicing of sarcomere genes. 9 38
20124440 2010
29
Connexin 43 remodeling induced by LMNA gene mutation Glu82Lys in familial dilated cardiomyopathy with atrial ventricular block. 9 38
20497714 2010
30
Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. 9 38
20206892 2010
31
A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a 'hot spot' region at exon 3: a case report. 9 38
20307303 2010
32
Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart. 9 38
19957088 2010
33
Identification of a new lamin A/C mutation in a Chinese family affected with atrioventricular block as the prominent phenotype. 9 38
20155465 2010
34
Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. 9 38
20160190 2010
35
Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 9 38
20102927 2010
36
Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. 9 38
20022821 2010
37
Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. 9 38
18778861 2010
38
Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. 9 38
19744495 2010
39
[LMNA gene and dilated cardiomyopathy]. 9 38
20193191 2009
40
Novel mutations in beta-myosin heavy chain, actin and troponin-I genes associated with dilated cardiomyopathy in Indian population. 9 38
20086309 2009
41
R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. 9 38
20092787 2009
42
Stimulation of cardiac beta-adrenoceptors targets connexin 43. 9 38
19719781 2009
43
The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors. 9 38
19719782 2009
44
Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. 9 38
19406126 2009
45
Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy. 9 38
20031601 2009
46
Validation of high-resolution DNA melting analysis for mutation scanning of the LMNA gene. 9 38
19318026 2009
47
Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. 9 38
19384091 2009
48
Acute dilated cardiomyopathy in a patient with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase. 9 38
19083141 2009
49
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 9 38
19261493 2009
50
Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. 9 38
19427440 2009

Variations for Dilated Cardiomyopathy

ClinVar genetic disease variations for Dilated Cardiomyopathy:

6 (show top 50) (show all 1083)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TTN NM_001267550.2(TTN): c.82657G> T (p.Gly27553Ter) single nucleotide variant Pathogenic rs869178171 2:179428202-179428202 2:178563475-178563475
2 LMNA NM_005572.3(LMNA): c.1494G> A (p.Trp498Ter) single nucleotide variant Pathogenic rs57730570 1:156106909-156106909 1:156137118-156137118
3 TTN NM_001267550.2(TTN): c.90706G> T (p.Glu30236Ter) single nucleotide variant Pathogenic rs974510652 2:179416921-179416921 2:178552194-178552194
4 TTN NM_001267550.2(TTN): c.51581G> A (p.Trp17194Ter) single nucleotide variant Pathogenic rs1553692290 2:179474569-179474569 2:178609842-178609842
5 DMD NM_004006.2(DMD): c.4838G> A (p.Trp1613Ter) single nucleotide variant Pathogenic rs1557315928 X:32398634-32398634 X:32380517-32380517
6 subset of 81 genes:GNB1 GRCh37/hg19 1p36.33-36.31(chr1: 834101-6076140) copy number loss Pathogenic 1:834101-6076140 :0-0
7 MYH6 NM_002471.3(MYH6): c.735T> G (p.Phe245Leu) single nucleotide variant Pathogenic rs1263987728 14:23873505-23873505 14:23404296-23404296
8 TTN NM_001267550.2(TTN): c.47961del (p.Gly15988fs) deletion Pathogenic rs1553707780 2:179481655-179481655 2:178616928-178616928
9 NKX2-5 NM_004387.4(NKX2-5): c.711C> A (p.Tyr237Ter) single nucleotide variant Pathogenic rs1554093433 5:172659836-172659836 5:173232833-173232833
10 BAG3 NM_004281.3(BAG3): c.252_258dup (p.Pro87fs) duplication Pathogenic 10:121429434-121429440 10:119669922-119669928
11 RBM20 NM_001134363.3(RBM20): c.1913C> T (p.Pro638Leu) single nucleotide variant Pathogenic rs267607003 10:112572068-112572068 10:110812310-110812310
12 MYBPC3 NM_000256.3(MYBPC3): c.1624G> C (p.Glu542Gln) single nucleotide variant Pathogenic rs121909374 11:47364129-47364129 11:47342578-47342578
13 SCN5A NM_000335.4(SCN5A): c.4780G> C (p.Asp1594His) single nucleotide variant Pathogenic rs137854607 3:38595800-38595800 3:38554309-38554309
14 TNNT2 NM_000364.4(TNNT2): c.451C> T (p.Arg151Trp) single nucleotide variant Pathogenic rs74315379 1:201333464-201333464 1:201364336-201364336
15 TTN NM_133379.5(TTN): c.2926T> C (p.Trp976Arg) single nucleotide variant Pathogenic rs267607155 2:179647707-179647707 2:178782980-178782980
16 PLN NM_002667.5(PLN): c.25C> T (p.Arg9Cys) single nucleotide variant Pathogenic rs111033559 6:118880109-118880109 6:118558946-118558946
17 MYH7 NM_000257.4(MYH7): c.1594T> C (p.Ser532Pro) single nucleotide variant Pathogenic rs121913642 14:23897088-23897088 14:23427879-23427879
18 LMNA NM_005572.3(LMNA): c.16C> T (p.Gln6Ter) single nucleotide variant Pathogenic rs61046466 1:156084725-156084725 1:156114934-156114934
19 LMNA NM_005572.3(LMNA): c.585C> G (p.Asn195Lys) single nucleotide variant Pathogenic rs28933091 1:156104265-156104265 1:156134474-156134474
20 LMNA NM_005572.3(LMNA): c.608A> G (p.Glu203Gly) single nucleotide variant Pathogenic rs28933092 1:156104288-156104288 1:156134497-156134497
21 TPM1 NM_001018005.2(TPM1): c.688G> A (p.Asp230Asn) single nucleotide variant Pathogenic rs199476317 15:63354462-63354462 15:63062263-63062263
22 SCN5A NM_000335.4(SCN5A): c.665G> A (p.Arg222Gln) single nucleotide variant Pathogenic rs45546039 3:38655272-38655272 3:38613781-38613781
23 TNNI3 NM_000363.5(TNNI3): c.544G> A (p.Glu182Lys) single nucleotide variant Pathogenic rs397516355 19:55665403-55665403 19:55154035-55154035
24 TNNT2 NM_000364.4(TNNT2): c.422G> A (p.Arg141Gln) single nucleotide variant Pathogenic rs397516464 1:201333493-201333493 1:201364365-201364365
25 TNNT2 NM_000364.4(TNNT2): c.641_643AGA[3] (p.Lys217del) short repeat Pathogenic rs45578238 1:201331099-201331101 1:201361971-201361973
26 DES NM_001927.4(DES): c.38C> T (p.Ser13Phe) single nucleotide variant Pathogenic rs62636495 2:220283222-220283222 2:219418500-219418500
27 PLN NM_002667.5(PLN): c.37_39AGA[1] (p.Arg14del) short repeat Pathogenic rs397516784 6:118880124-118880126 6:118558961-118558963
28 DSP NM_004415.4(DSP): c.1146del (p.Phe382fs) deletion Pathogenic rs397516913 6:7568019-7568019 6:7567786-7567786
29 LMNA NM_005572.3(LMNA): c.1526dupC (p.Thr510Tyrfs) duplication Pathogenic rs58013325 1:156106941-156106941 1:156137150-156137150
30 LMNA NM_005572.3(LMNA): c.348dup (p.Lys117fs) duplication Pathogenic rs267607646 1:156085057-156085057 1:156115266-156115266
31 LMNA NM_005572.3(LMNA): c.607G> A (p.Glu203Lys) single nucleotide variant Pathogenic rs61195471 1:156104287-156104287 1:156134496-156134496
32 LMNA NM_005572.3(LMNA): c.673C> T (p.Arg225Ter) single nucleotide variant Pathogenic rs60682848 1:156104629-156104629 1:156134838-156134838
33 LMNA NM_005572.3(LMNA): c.700C> T (p.Gln234Ter) single nucleotide variant Pathogenic rs267607573 1:156104656-156104656 1:156134865-156134865
34 LMNA NM_005572.3(LMNA): c.958del (p.Leu320fs) deletion Pathogenic rs397517915 1:156105713-156105713 1:156135922-156135922
35 LMNA NM_005572.3(LMNA): c.961C> T (p.Arg321Ter) single nucleotide variant Pathogenic rs267607554 1:156105716-156105716 1:156135925-156135925
36 LMNA NM_005572.3(LMNA): c.244G> A (p.Glu82Lys) single nucleotide variant Pathogenic rs59270054 1:156084953-156084953 1:156115162-156115162
37 DSP NM_004415.3(DSP): c.2131_2132delAG (p.Ser711Cysfs) deletion Pathogenic rs587782927 6:7574319-7574320 6:7574086-7574087
38 LMNA NM_005572.3(LMNA): c.1086del (p.Leu363fs) deletion Pathogenic rs58389804 1:156105841-156105841 1:156136050-156136050
39 TTN NM_001267550.2(TTN): c.49648+2delT deletion Pathogenic rs727504851 2:179477886-179477886 2:178613159-178613159
40 TTN NM_001267550.2(TTN): c.80716C> T (p.Arg26906Ter) single nucleotide variant Pathogenic rs727505284 2:179430143-179430143 2:178565416-178565416
41 LMNA NM_005572.3(LMNA): c.710T> C (p.Phe237Ser) single nucleotide variant Pathogenic rs730880132 1:156104666-156104666 1:156134875-156134875
42 TNNT2 NM_000364.4(TNNT2): c.547C> T (p.Arg183Trp) single nucleotide variant Pathogenic rs727503512 1:201332477-201332477 1:201363349-201363349
43 BAG3 NM_004281.3(BAG3): c.925C> T (p.Arg309Ter) single nucleotide variant Pathogenic rs869248137 10:121435991-121435991 10:119676479-119676479
44 MYBPC3 NM_000256.3(MYBPC3): c.2504del (p.Arg835fs) deletion Pathogenic rs876657704 11:47359040-47359040 11:47337489-47337489
45 CSRP3 NM_003476.5(CSRP3): c.420G> C (p.Trp140Cys) single nucleotide variant Pathogenic 11:19206587-19206587 11:19185040-19185040
46 BAG3 NM_004281.3(BAG3): c.730C> T (p.Gln244Ter) single nucleotide variant Pathogenic/Likely pathogenic rs876657634 10:121431989-121431989 10:119672477-119672477
47 TTN NM_001267550.2(TTN): c.86437G> T (p.Glu28813Ter) single nucleotide variant Pathogenic/Likely pathogenic rs868494032 2:179424422-179424422 2:178559695-178559695
48 TTN NM_001267550.2(TTN): c.83515C> T (p.Arg27839Ter) single nucleotide variant Pathogenic/Likely pathogenic rs869312118 2:179427344-179427344 2:178562617-178562617
49 LMNA NM_005572.3(LMNA): c.356+1G> C single nucleotide variant Pathogenic/Likely pathogenic rs794728589 1:156085066-156085066 1:156115275-156115275
50 TTN NM_001267550.2(TTN): c.85090C> T (p.Arg28364Ter) single nucleotide variant Pathogenic/Likely pathogenic rs770038577 2:179425769-179425769 2:178561042-178561042

Expression for Dilated Cardiomyopathy

Search GEO for disease gene expression data for Dilated Cardiomyopathy.

Pathways for Dilated Cardiomyopathy

Pathways related to Dilated Cardiomyopathy according to KEGG:

37
# Name Kegg Source Accession
1 Dilated cardiomyopathy (DCM) hsa05414

Pathways related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 TPM1 TNNT2 TNNI3 SCN5A PLN MYH7
2
Show member pathways
12.62 TTN TPM1 TNNT2 TNNI3 SCN5A PLN
3 12.34 TPM1 TNNT2 TNNI3 LMNA DES
4
Show member pathways
12.02 LMNA DSP DSG2 DMD DES
5 11.81 TNNT2 TNNI3 NKX2-5
6
Show member pathways
11.72 LMNA DSP DSG2
7 11.65 TPM1 TNNT2 TNNI3 MYH7 MYH6
8
Show member pathways
11.63 TTN TPM1 TNNT2 TNNI3 PLN MYH7
9 11.45 SCN5A PLN LMNA DSP
10 11.42 TTN TPM1 TNNT2 TNNI3 MYH6 MYBPC3
11 11.38 TNNT2 TNNI3 SCN5A NKX2-5 MYH6
12 10.84 NKX2-5 MYH7

GO Terms for Dilated Cardiomyopathy

Cellular components related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 sarcolemma GO:0042383 9.71 SCN5A DMD DES
2 stress fiber GO:0001725 9.65 TPM1 MYH7 MYH6
3 lateral plasma membrane GO:0016328 9.63 SCN5A DSG2 DMD
4 myofibril GO:0030016 9.63 TPM1 TNNT2 TNNI3 MYH7 MYH6 DMD
5 intercalated disc GO:0014704 9.62 SCN5A DSP DSG2 DES
6 Z disc GO:0030018 9.61 TTN SCN5A MYH7 MYH6 MYBPC3 DMD
7 striated muscle thin filament GO:0005865 9.58 TTN TNNT2 MYBPC3
8 cardiac myofibril GO:0097512 9.56 TNNT2 TNNI3 MYBPC3 DES
9 contractile fiber GO:0043292 9.55 TNNI3 DES
10 myosin filament GO:0032982 9.54 MYH7 MYH6 MYBPC3
11 muscle myosin complex GO:0005859 9.52 MYH7 MYH6
12 fascia adherens GO:0005916 9.51 DSP DES
13 troponin complex GO:0005861 9.49 TNNT2 TNNI3
14 cardiac Troponin complex GO:1990584 9.43 TNNT2 TNNI3
15 sarcomere GO:0030017 9.23 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6

Biological processes related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.83 TNNI3 PLN CSRP3
2 sarcomere organization GO:0045214 9.8 TTN TPM1 TNNT2 NKX2-5 MYH6 MYBPC3
3 positive regulation of ATPase activity GO:0032781 9.77 TPM1 TNNT2 MYBPC3
4 regulation of heart contraction GO:0008016 9.77 TPM1 TNNT2 PLN MYH6 DES
5 regulation of heart rate GO:0002027 9.76 SCN5A MYH7 MYH6 DMD
6 muscle contraction GO:0006936 9.76 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
7 regulation of heart rate by cardiac conduction GO:0086091 9.75 SCN5A DSP DSG2
8 skeletal muscle contraction GO:0003009 9.74 TNNT2 TNNI3 MYH7
9 cardiac muscle tissue morphogenesis GO:0055008 9.73 TTN NKX2-5 MYBPC3
10 regulation of the force of heart contraction GO:0002026 9.73 PLN MYH7 MYH6 CSRP3
11 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.73 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
12 regulation of muscle contraction GO:0006937 9.72 TPM1 TNNT2 TNNI3
13 cardiac myofibril assembly GO:0055003 9.71 TTN MYBPC3 CSRP3
14 striated muscle contraction GO:0006941 9.71 TTN TNNI3 MYH7 MYH6
15 cardiac muscle tissue development GO:0048738 9.7 PLN NKX2-5 CSRP3
16 cardiac muscle fiber development GO:0048739 9.69 TTN MYH6 MYBPC3
17 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0010880 9.68 PLN DMD
18 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.67 PLN DMD
19 intermediate filament organization GO:0045109 9.67 DSP DES
20 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.67 PLN DMD
21 adult heart development GO:0007512 9.67 NKX2-5 MYH7 MYH6
22 positive regulation of sodium ion transport GO:0010765 9.66 SCN5A NKX2-5
23 heart contraction GO:0060047 9.65 TNNI3 NKX2-5
24 cardiac muscle hypertrophy in response to stress GO:0014898 9.65 MYH7 MYH6
25 skeletal muscle thin filament assembly GO:0030240 9.65 TTN MYBPC3
26 negative regulation of ATPase activity GO:0032780 9.65 TNNT2 TNNI3 PLN
27 regulation of cardiac muscle cell contraction GO:0086004 9.64 SCN5A PLN
28 transition between fast and slow fiber GO:0014883 9.64 MYH7 MIR499A
29 skeletal muscle myosin thick filament assembly GO:0030241 9.63 TTN MYBPC3
30 response to denervation involved in regulation of muscle adaptation GO:0014894 9.63 SCN5A DMD
31 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.62 DSP DSG2
32 cardiac muscle hypertrophy GO:0003300 9.62 TTN CSRP3
33 ventricular cardiac muscle cell development GO:0055015 9.61 NKX2-5 LMNA
34 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.61 DSP DSG2
35 muscle filament sliding GO:0030049 9.61 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
36 desmosome organization GO:0002934 9.6 DSP DSG2
37 detection of muscle stretch GO:0035995 9.58 TTN CSRP3
38 cardiac muscle contraction GO:0060048 9.36 TTN TPM1 TNNT2 TNNI3 SCN5A NKX2-5

Molecular functions related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.71 TTN SCN5A MYH7 MYH6
2 actin filament binding GO:0051015 9.63 TTN TPM1 TNNI3 MYH7 MYH6 MYBPC3
3 structural constituent of cytoskeleton GO:0005200 9.56 TPM1 DSP DMD DES
4 microfilament motor activity GO:0000146 9.52 MYH7 MYH6
5 muscle alpha-actinin binding GO:0051371 9.51 TTN MYBPC3
6 nitric-oxide synthase binding GO:0050998 9.49 SCN5A DMD
7 actin-dependent ATPase activity GO:0030898 9.48 MYH7 MYH6
8 actinin binding GO:0042805 9.46 TTN CSRP3
9 telethonin binding GO:0031433 9.43 TTN CSRP3
10 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.37 DSP DSG2
11 structural constituent of muscle GO:0008307 9.35 TTN TPM1 MYBPC3 DMD CSRP3
12 troponin C binding GO:0030172 9.32 TNNT2 TNNI3
13 actin binding GO:0003779 9.23 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
14 identical protein binding GO:0042802 10.01 TTN TPM1 PLN MYBPC3 DES CSRP3

Sources for Dilated Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....